N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
PubChem CID: 71811910
Omaveloxolone is a semi-synthetic triterpenoid drug. It is an Nrf2 activator that is approved for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. It has a role as an antioxidant, an antineoplastic agent, an anti-inflammatory agent and a cardioprotective agent. It is a secondary carboxamide, a nitrile, a pentacyclic triterpenoid, a cyclic terpene ketone and an organofluorine compound. It derives from a hydride of an oleanane.
Canonical SMILES
SMILES: This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Trials and conditions connected to Omaveloxolone